Skip to main content

Table 1 Baseline demographic and disease characteristics of CHB patients treated with telbivudine (n = 108)

From: Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections

Characteristic

N (SD or %)

Age, years

40 (±10)

Sex, male, n (%)

87 (81%)

HBV DNA, log10IU/mL

6.0 (±1.3)

HBsAg titre, log10IU/mL

3.6 (±0.5)

ALT, U/L

135 (±131)

CK, U/L

129 (±61)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us